Man­u­fac­tur­ing isn’t an after­thought. It’s our foundation.

Manufacturing

We deliver durable medicines at scale by integrating product engineering, analytical char­ac­ter­i­za­tion, and process innovation to enable mass dis­tri­b­u­tion. We pair HOPSON™, Kriya’s large-scale proprietary structured data platform, with cutting-edge infra­struc­ture to drive exponential advance­ments in man­u­fac­tur­ing performance and product quality.

Technicians in cleanroom suits working on a bioreactor in a manufacturing suite
Product conceptualization 
 5 classes of vectorized proteins Within the first six years Vector genome design 
 >2,700 plasmids created Route of administration 
 4 direct-to-tissue routes Serotype selection 
 4 AAV serotypes Manufacturing assessment 
 >100 batches screened In vivo testing 
 >10 proof-of-concept programs Medicines 
 5 programs in the clinic

An integrated product engine.

Traditional drug development treats discovery, development and man­u­fac­tur­ing as separate functions and sequential workstreams.

Kriya integrates all functions, from vector engineering to process development, analytical sciences, man­u­fac­tur­ing, and preclinical and clinical development, into one continuous and iterative system.

Scientists, engineers and floor operators work side by side from the earliest stages of development, ensuring every inves­ti­ga­tion­al medicine is designed not only for clinical success but also for man­u­fac­tura­bil­i­ty, scalability, and commercial success.

By integrating disciplines ranging from early research to commercial production, Kriya minimizes technology transfers, reduces man­u­fac­tur­ing risk and accelerates scale-up.

Our Inves­ti­ga­tion­al Medicines

Our integrated product engine takes potential medicines from concept to clinic and beyond.

Since our founding in 2019, Kriya has run over 100 engineering and GMP batches at 50L scale or greater – generating over 80 million proprietary data points structured in HOPSON™, our data platform that powers the intelligent systems behind our product engine.

Our medicines enter the clinic already built to scale, with industry-leading quality and pro­duc­tiv­i­ty that supports our commercial ambitions.

Our Approach to Data
Rich Guerra standing on a catwalk above the facility mechanical systems

Expert spotlight

“We’ve been intentional about building our man­u­fac­tur­ing platform, from pilot to commercial scale. At the heart of it is a team that col­lab­o­rates every day, applying discipline and expertise to develop durable medicines for chronic diseases.”

Rich Guerra
Vice-President, Man­u­fac­tur­ing & Plant Manager

Purpose-built to support the development and com­mer­cial­iza­tion of durable medicines.

Located in Research Triangle Park, North Carolina, Kriya’s world-class man­u­fac­tur­ing campus supports a platform man­u­fac­tur­ing process that can utilize the same core unit operations from research scale through commercial production, enabling seamless scale-up without costly process redesigns and minimizing technology transfer risk. 

Our vertically integrated capa­bil­i­ties include:

  • GMP production at 50L, 500L, and 3,000L bioreactor scales
  • Upstream and downstream process development
  • In-house analytical development and quality control testing
  • Internal automated fill-finish and vial filling operations

Kriya’s man­u­fac­tur­ing strategy has been selected by the U.S. Food and Drug Admin­is­tra­tion for par­tic­i­pa­tion in the FDA PreCheck Pilot Program — a competitive initiative recognizing companies investing in modern man­u­fac­tur­ing tech­nolo­gies, integrated infra­struc­ture, and commercial readiness.

Explore HOPSON™ our integrated data platform. Our Data Kriya Announces Publication of Preclinical Data Showing AAV-FGF21 Gene Therapy Extended Health Span and Lifespan in Aged Mice Kriya Selected for FDA PreCheck Pilot Program

Disclaimer

Kriya’s durable medicines are inves­ti­ga­tion­al and have not been approved as safe or effective by any regulatory health authority.